NCT04567329 - Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study) | Biotech Hunter

Enrollment

620

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions

Dry Eye Disease

Interventions

DRUG

NOV03

100% perfluorohexyloctane

DRUG

Saline Solution

0.6% sodium chloride solution

Trial Locations (35)

14618

Bausch Site 208, Rochester

21078

Bausch Site 228, Havre de Grace

23502

Bausch Site 220, Norfolk

27262

Bausch site 233, High Point

28387

Bausch site 232, Southern Pines

28803

Bausch Site 210, Asheville

30260

Bausch Site 204, Morrow

33484

Bausch Site 211, Delray Beach

37215

Bausch Site 215, Nashville

40220

Bausch Site 207, Louisville

43215

Bausch Site 223, Columbus

44115

Bausch Site 216, Cleveland

45247

Bausch Site 201, Cincinnati

55431

Bausch Site 231, Bloomington

60169

Bausch site 218, Hoffman Estates

60616

Bausch Site 209, Chicago

63090

Bausch Site 217, Washington

63128

Bausch Site 229, St Louis

63131

Bausch Site 224, St Louis

66210

Bausch Site 230, Overland Park

77573

Bausch Site 212, League City

78209

Bausch site 234, San Antonio

78215

Bausch Site 222, San Antonio

78230

Bausch Site 203, San Antonio

78613

Bausch Site 219, Cedar Park

78731

Bausch site 235, Austin

81501

Bausch site 225, Grand Junction

85032

Bausch Site 206, Phoenix

90301

Bausch Site 214, Inglewood

92545

Bausch Site 221, Hemet

92562

Bausch Site 226, Murrieta

92683

Bausch site 236, Westminster

92705

Bausch Site 213, Santa Ana

92843

Bausch Site 202, Garden Grove

98119

Bausch Site 227, Seattle

All Listed Sponsors

lead

Bausch & Lomb Incorporated

INDUSTRY